Phase 2 Study of Mosunetuzumab and Zanubrutinib Treatment for Adults With Relapsed or Refractory Marginal Zone Lymphoma

What this Trial Is About

Researchers are studying the combination of mosunetuzumab and zanubrutinib to evaluate its safety and effectiveness in treating patients with relapsed or refractory marginal zone lymphoma MZL. This phase 2 trial aims to determine the best complete response rate from this treatment and also examines overall response, duration of response, time until next treatment, progression-free survival, overall survival, and how well patients tolerate the therapy. Additionally, the study explores the role of tumor volume and biomarkers related to treatment response and resistance in MZL. Participants receive mosunetuzumab and zanubrutinib, both given by intravenous infusion, as part of a single treatment group. The study does not use a placebo or multiple comparison groups. Treatment details such as dosing schedules are not specified here, but the combination therapy is assessed throughout the trial. The study is designed to follow patients through treatment and monitor their response and safety outcomes over time. During the study, participants undergo evaluations to monitor safety and measure treatment effects, including imaging scans and laboratory tests to assess tumor size and organ function. Researchers track adverse events and treatment responses for an average of one year. The total participation duration extends until study completion in late 2028. This ongoing monitoring helps researchers understand how well the treatment works and its safety profile in patients with relapsed or refractory MZL.

A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma